

Addendum to Chapter 10: AIDS-associated lymphoma

Matthew D. Volm and Jamie H. Von Roenn

Due to the addition of new material to Chapter 10, the last two pages of references have been moved to the back of the volume to allow for all updates.

94. DeAngelis LM. 1991. Primary central nervous system lymphoma: a new clinical challenge. *Neurology* 41:619–621.
95. Bashir RM, Harris NL, Hochberg FH, Singer RM. 1989. Detection of Epstein–Barr virus in CNS lymphomas by in-situ hybridization. *Neurology* 39:813–817.
96. MacMahon EME, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, MacArthur JC, Ambinder RF. 1991. Epstein–Barr virus in AIDS-related primary central nervous system lymphoma. *Lancet* 338:969–973.
97. Finke J, Fritzen R, Ternes P, Trivedi P, Bross KJ, Lange W, Mertelsman R, Dolken G. 1992. Expression of Bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein–Barr virus genes. *Blood* 80:459.
98. Henderson R, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. 1991. Induction of Bcl-2 expression by Epstein–Barr latent membrane protein 1 protects infected B cells from programmed cell death. *Cell* 65:1107.
99. Seite P, Hillion J, D'Agay MF, Gaulard P, Cazals D, Badoux F, Berger R, Larsen CJ. 1993. Bcl-2 gene activation and protein expression in follicular lymphoma: a report on 64 cases. *Leukemia* 7:410.
100. Kondo E, Yoshino T, Nakamura S, Takahashi K, Teramoto N, Hayashi K, Akagi T. 1994. Bcl-2 regulation in normal resting lymphocytes and lymphoblasts. *Jpn J Cancer Res* 65:260.
101. Camilleri-Broet S, Davi F, Feuillard J, Bourgeois C, Seilhean D, Hauw JJ, Raphael M. 1995. High expression of latent membrane protein 1 of Epstein–Barr virus and Bcl-2 oncoprotein in acquired immunodeficiency-related primary brain lymphomas. *Blood* 86:432–435.
102. Rosenblum ML, Levy RM, Bredesen DE. 1988. Neurosurgical implications of the acquired immunodeficiency syndrome (AIDS). *Clin Neurosurg* 34:419–445.
103. Ciricillo SF, Rosenblum ML. 1990. Use of CT and MR imaging to distinguish intracranial lesion and to define the need for biopsy in AIDS patients. *J Neurosurg* 73:720–724.
104. Cingolani A, De Luca A, Larocca LM, Ammassari A, Scerrati M, Antinori A, Ortona L. 1998. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma [see comments]. *Journal of the National Cancer Institute* 90:364–369.
105. Roberts TC, Storch GA. 1997. Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis. *Journal of Clinical Microbiology* 35:268–269.
106. Pintado V, Navas E, Mitjavila M, San Millan J, Quereda C, Guerrero A. 1996. Thallium-201 SPECT in differentiating lymphoma from nonmalignant CNS lesions in AIDS patients. *Program Abstr Intersci Conf Antimicrob Agents Chemother* 208.
107. Lorberboym M, Estok L, Machac J, Germano I, Sacher M, Feldman R, Wallach F,

- Dorfman D. 1996. Rapid differential diagnosis of cerebral toxoplasmosis and primary central nervous system lymphoma by thallium-201 SPECT. *Journal of Nuclear Medicine* 37:1150–1154.
108. Ciricillo SF, Rosenblum ML. 1994. AIDS and the neurosurgeon — an update. *Advances & Technical Standards in Neurosurgery* 21:155–182.
109. Woodman R, Shin K, Pincus G. 1985. Primary non-Hodgkin's lymphoma of the brain: a review. *Medicine* 64:425–430.
110. DeAngelis LM, Yahalom J, Thaler H, Kher U. 1992. Combined modality therapy for primary CNS lymphoma. *J Clin Oncol* 10:635–643.
111. Forsythe PA, Yahalom J, DeAngelis LM. 1994. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. *Neurology* 44:1473–1479.

Index

A

ACTG 142 trial, 253–254, 253t

Acute lymphoblastic leukemia, 307–327
B-cell lineage of, 312
chemical exposure and, 309
in children, 307
classification and characterization of, 309–314

clinical manifestations of, 315–317, 315t

cytogenic characterization of, 313–314

drug resistance in, 314

epidemiology of, 308

etiology of, 308–309

immunophenotyping of, 310–313, 311f

morphology of, 309, 309t

prognostic features of, 317–318, 317t

radiation exposure and, 308–309

T lymphoblast ontogeny in, 312–313

treatment of, 318–325 (*See also* Acute lymphoblastic leukemia, treatment of) vs. lymphoblastic lymphoma (LBL), 58

Acute lymphoblastic leukemia, treatment of, 318–325
bone marrow transplantation in, 324–325
categories of, 319
consolidation therapy in, 321
future directions in, 325–327
maintenance therapy in, 321
mature B-cell in, 325
newly diagnosed adult in, 319–323, 320f
relapsed or refractory disease in, 323–324
sanctuary sites in, 321–322
whole-brain radiation therapy in, 322
Acute myelogenous leukemia (AML), 195–219. *See also* Hematopoietic growth factors, and leukemia
Acute myeloid leukemia (AML), 281–284
bone marrow transplantation for, 283
immunomodulators for, 283–284

interleukin-2 for, 281–283, 282t
Acute promyelocytic leukemia, current approaches to, 125–143
arsenic compounds in, 141
ATRA therapy in, clinical trials of, 128–135 (*See also* All-trans retinoic acid (ATRA), clinical trials of)
ATRA therapy in, complications of, 137–139
ATRA therapy in, costs of, 139–140
ATRA therapy in, pharmacology of, 127–128
ATRA therapy in, role of, 126–127
diagnostic criteria in, 125–126
ligand-receptor interactions in, 142
postremission therapy in, 135–136
prognostic factors in, 136–137
retinoids in, other, 140–141
stem cell transplants in, 141–142
transcriptional regulation and therapy in, 142–143
Acute promyelocytic leukemia, molecular biology of, 75–112
critical advances in, 111–112
gene break points in, 77f
molecular diagnostics in, 108–111 (*See also* Acute promyelocytic leukemia, molecular diagnostics for)
PML gene in, 76–79 (*See also* PML gene)
PML-RAR α in [[comp:l:c Greek alpha]], 84–91 (*See also* PML-RAR α)
RAR α (alpha receptor for retinoic acid) in, 79–84 (*See also* RAR α (alpha receptor for retinoic acid))
RAR α fusion proteins in, alternative, 104–108 (*See also* RAR α fusion proteins, alternative)
retinoic acid resistance in, 97–104 (*See also* Retinoic acid resistance)

- Acute promyelocytic leukemia (*Continued*)
 - retinoid response in, 92–97 (*See also* Retinoid response)
 - translocation and fusion genes in, 76t
- Acute promyelocytic leukemia, molecular
 - diagnostics for, 108–111
 - fresh cell studies in, 102–103
 - methods overview in, 108
 - RAR α -PML detection in, 110–111
 - RT-PCR in, for APL diagnosis, 108–109
 - RT-PCR in, for MRD detection, 109
 - RT-PCR in, technical improvements in, 109–110
 - studies in, early, 109
 - studies in, future, 111
 - studies in, recent, 110
- Adoptive immunotherapy, for diffuse
 - aggressive lymphoma, 64
- AIDS-associated lymphoma, 241–260
 - conclusions in, 259–260
 - epidemiology of, 241–243
 - extranodal sites in, 250, 250t
 - histology of, 243
 - pathogenesis of, 244–250 (*See also* AIDS-associated lymphoma, pathogenesis of)
 - presentation of, 250–251
 - primary CNS lymphoma in, 257–259
 - prognostic factors for, 251
 - staging of, 250–251
 - treatment of, 251–257 (*See also* AIDS-associated lymphoma, treatment of)
- AIDS-associated lymphoma, pathogenesis
 - of, 244–250
 - B-cell stimulation in, 247–248
 - cytokines in, endogenous, 248–249
 - EBV in, 245–246
 - Kaposi's sarcoma herpes virus (KSHV) in, 246–247
 - molecular genetics in, 249–250
 - posttransplant lymphomas vs. HIV-associated lymphomas in, 244t
 - posttransplant lymphoproliferative disorders paradigm in, 244–245
 - T-cell function loss in, 247–248
- AIDS-associated lymphoma, treatment of, 251–257
 - ACTG 142 trial in, 253–254, 253t
 - antiretroviral therapy in, 255–256
 - chemotherapy in, 255–256
 - CNS disease in, secondary, 255
 - colony stimulating factors in, 254–255
 - dose intensity in, 252–254
 - m-BACOD regimen in, low dose, 252, 252t
 - myelosuppression in, 254–255
 - new approaches in, 256–257
 - refractory or relapsed conditions in, second-line therapy for, 256
- Allogeneic transplants, 181–184
 - for ALL vs. AML, 324
 - alternate donors for, 183
 - clinical trial results for, 182, 182t
 - graft-*versus*-myeloma effect in, 184
 - in myelodysplasia, 346, 352
 - prognostic features for, 183
 - vs. autologous transplants, 181, 184–186
- All-*trans* retinoic acid (ATRA)
 - in APL gene translocations, 76t
 - for chronic myeloid leukemia (CML), 279
 - for myelodysplasia, 339t, 342
 - in PML-RAR α *in vitro* studies, 89
 - in PML-RAR α isoforms, 85–86
 - and pregnancy, 137–138
 - in retinoid response, 92–97
- All-*trans* retinoic acid (ATRA), clinical
 - trials of, 128–135
 - Argentinean series on, 134
 - British MRC ATRA Trial on, 134
 - EORTC on, 133–134
 - European APL 91 study on, 130–132
 - GIMEMA on, 133–134
 - Japan Adult Leukemia Study Group (JALSG) on, 129–130
 - M.D. Anderson Cancer Center on, 133
 - New York trial on, 129
 - North American Intergroup 0129 study on, 132
 - remission rates in, 129, 134–135
 - in vitro* study results and, 128
- Alpha interferon
 - for B-cell malignancies, 286–288, 287t
 - for myeloid leukemias, 275
- Alpha receptor for retinoic acid (RAR α).
 - See* RAR α
- Am580, 140
- Anaplastic large cell lymphoma (ALCL)
 - in non-Hodgkin's lymphoma classification, 16–18, 17f
 - therapy for, 60–61
- Anaplastic lymphoma kinase (ALK), 17–18, 60
- Androgens, 353
- Anthracycline
 - in adult ALL, 319
 - in ATRA therapy, 135
- Antimicrobial function enhancement, in leukemia, 207–210

cytokines in, 207–208, 208t
fungal infection mortality in, 209–210, 209t
GM-CSF in, 208–210
Antiretroviral therapy
in AIDS-associated lymphoma, 255–256
for B-cell non-Hodgkin's lymphoma (NHL), 242
Apoptosis
in myelodysplasia, 335–336
in S phase cell recruitment, 211–212
Arsenic compounds, for acute promyelocytic leukemia, 141
Aspergillus fumigatus, in AML, 207, 209t
ATRA. *See* all-trans retinoic acid (ATRA)
Australian Leukemia Study Group, 138–139
Austrian Cooperative Group, 287–288, 287t
Autocrine/paracrine loop interruption, 216–218
Autologous transplants
for multiple myeloma, 172–180
vs. allogeneic transplants, 184–186
Azacytadine, 343
AZT, 242

B

B-cell
Epstein-Barr virus on, 28–29, 28f
myeloma, 286–289 (*See also* B-cell malignancies, novel approaches to)
stimulation of, in AIDS-associated lymphoma, 247–248
B-cell lymphoma
in anaplastic large cell lymphoma classification, 17
from MALT lymphoma, 13
as marginal zone lymphoma, 12
in node-based marginal zone lymphoma, 14
ontogeny schematic of, 311f
in REAL classification, 7–8, 8t
vs. T-cell, 4, 6
B-cell malignancies, novel approaches to, 286–289
alpha interferon in, 286–288, 287t
cyclosporine A (CSA) in, 288–289
erythropoietin in, 288
interleukin-2 in, 288
interleukin-4 in, 292
myeloma in, 286–288
B-cell malignancies, resistance to, 267–272
future directions in, 271–272
human studies in, 270–272

preclinical experimental models in, 267–270
B-cell non-Hodgkin's lymphoma (NHL), 241
antiretroviral drugs on, 242
Working Formulation categories for, 243, 243t
Bcl-1 gene, 11
Bcl-2 gene
in autocrine/paracrine loops, 216
in B-cell malignancies, 270–271
in primary CNS lymphoma, 258
in retinoic acid resistance, 104
in retinoid response, 94
Bcl-6 gene, in HIV-associated lymphomas, 249–250
Benzene, 309
Bestatin (Ubenimex), 283–284
B2-microglobulin in [[comp-l.c. Greek beta]], in multiple myeloma, 161, 176
Bone marrow transplantation
for acute myeloid leukemia (AML), 283
for anaplastic large cell lymphoma (ALCL), 61
for diffuse aggressive lymphoma, initial treatment of, 52–53, 53t
for diffuse aggressive lymphoma, relapsed, 56
interleukin-2 in, 291–292
for multiple myeloma (*See* Multiple myeloma, transplantation for)
Breakpoint regions, in PML-RAR α , 84–85
British MRC ATRA Trial, 134
Burkitt's lymphoma
C-myc rearrangements in, 249
Epstein-Barr virus in, 35–36, 245–246
therapy for, 57–58
Busulfan (BU), 276–277, 277t

C

Canadian Cooperative Group, 287–288, 287t
Cancer and Leukemia Group B study
on chronic myeloid leukemia, 276
on leukemia neutropenia, 205
Candida albicans, in AML, 207, 209t
CD4 cells
in B-cell malignancies, 270
in HIV-associated lymphomas, 242
CD5 cells
in mantle cell lymphoma, 11
monoclonal antibodies and, 231
CD8 cells, in EBV infection, 31
CD30, 17, 60

- Cell differentiation, induction of, 214
 - Cellular expression, of acute promyelocytic leukemia, 78–79
 - Central nervous system (CNS) disease
 - in acute lymphoblastic lymphoma, 316
 - in AIDS-associated lymphoma, 255, 257–259
 - primary, 242
 - Centroblast, 3
 - Centrocyte, 3
 - Chemotherapy
 - for AIDS-associated lymphoma, 255–256
 - for anaplastic large cell lymphoma (ALCL), 16
 - for B-cell malignancies, 270
 - for chronic myeloid leukemia, 276–277, 277t
 - for diffuse aggressive lymphomas, 50–53
 - for diffuse aggressive lymphomas, conventional-dose salvage, 55–56
 - for myelodysplasia, 286, 346, 348t–351t
 - for non-Hodgkin's lymphoma, 289–291, 290t
 - for primary adult ALL, 319–323
 - for primary CNS lymphoma, 259
 - 2-Chlorodeoxyadenosine (2-CDA), 230
 - CHOP regimen, 50
 - for anaplastic large cell lymphoma in (ALCL), 60–61
 - new approaches and, 51–54
 - vs. VMT, 57
 - Chromosome, translocation of
 - in acute lymphoblastic leukemia, 313–314
 - in acute promyelocytic leukemia, 76t
 - in anaplastic large cell lymphoma, 17–18, 60
 - in Burkitt's lymphoma, 35, 57–58, 313–314
 - in HIV-associated lymphomas, 249
 - in MALT lymphoma, 13
 - in mantle cell lymphoma, 11
 - 11Q13 in, 159–160
 - Chromosome 13, 159
 - Chronic Granulomatous Disease Study Group, 209
 - Chronic lymphocytic leukemia (CLL), 11
 - Chronic myeloid leukemia (CML), 276–281
 - accelerated CML in, 278
 - all-*trans* retinoic acid (ATRA) for, 279
 - donor leukocyte infusions for, 280
 - future directions in, 280–281
 - gamma interferon for, 279
 - interferon therapy for, 276–278, 277t
 - juvenile CML in, 280
 - low-dose cytarabine for, 278–279
 - C-myc gene, 20
 - in HIV-associated lymphomas, 245, 249
 - in multiple myeloma, 160
 - Colonization, follicular, 12
 - Colony stimulating factors. *See also* Granulocyte-macrophage colony stimulating factor (GM-CSF)
 - in AIDS-associated lymphoma, 254–255
 - Combination approaches, for cutaneous T-cell lymphoma, 236–237
 - Consolidation therapy, 321
 - COPA regimen, 290–291
 - C-reactive protein, in multiple myeloma, 162–163
 - Cutaneous T-cell lymphoma, 227–237
 - combination approaches for, 236–237
 - fusion toxin therapies for, 233–234
 - interleukin-2 for, 228
 - monoclonal antibodies for, 231–233
 - purine analogue therapy for, 229–231
 - retinoids for, 227–228
 - thymopentin for, 234–235
 - Cyclin D1 protein, 11
 - Cyclophosphamide, 319–320
 - Cyclosporine
 - for B-cell malignancies, 288–289
 - for cytopenias, 294
 - for lymphoproliferative disease, 32
 - for myelodysplasia, 354
 - Cytarabine
 - for adult ALL, 321
 - in ATRA therapy, 130, 135
 - for chronic myeloid leukemia (CML), 278–279
 - for relapsed ALL, 323
 - Cytogenetic abnormalities, in multiple myeloma, 158–160
 - Cytokines
 - activity factors for, in multiple myeloma, 161–164
 - in AIDS-associated lymphoma, 248–249
 - for AML neutropenia, 199–200, 200t
 - in AML priming therapy, 212, 213t
 - antileukemic effects of, 214–216
 - in B-cell malignancies, 268, 269t
 - in PML cellular expression, 78
 - Cytopenia, cyclosporine for, 294
- D**
- DAB₃₈₉IL-2, 233–234
 - DAB₄₈₆IL-2, 233
 - Danazol, 353–354

- Daunorubicin, in ATRA therapy, 130
- Dendritic cells, 292
- Deoxycoformycin (DCF), 229
- Desferrioxamine, subcutaneous, 354
- Dexamethasone
 - for AIDS-associated lymphoma, 258
 - in ATRA therapy, 138–139
- DHAP regimen, 54, 56
- Differentiation therapy, 338–343, 339t–341t
- Diffuse aggressive lymphoma, therapy for, 47–64
 - adoptive immunotherapy in, 64
 - anaplastic large cell lymphoma in (ALCL), 60–61
 - biology of, 48
 - Burkitt's and Burkitt's like lymphoma in, 57–58
 - cellular markers in, 50
 - chemotherapy in, conventional-dose salvage, 55–56
 - chemotherapy in, high dose, 56
 - chemotherapy in, with stem cell support, 52–53
 - classification of, 47–48, 48t
 - dose intensity in, 51–52
 - dose intensity in, without stem cell support, 52
 - elderly in, 56–57
 - high-dose sequential chemotherapy (HDSC) in, 54
 - high-risk disease patient determination in, 49–50
 - historical perspective to treatment in, 50–51
 - immunotherapy for, 62–64
 - immunotoxins in, 63
 - initial treatments in, 51–54
 - lymphoblastic lymphoma in, 58–60
 - monoclonal antibodies in, 62–63
 - peripheral T-cell lymphomas (PTCL) in, 61–62
 - prognostic factors for, 48, 49t
 - radioimmunotherapy in, 63
 - relapsed aggressive lymphoma treatments in, 55–56
 - retinoic acid in, 62
 - small noncleaved cell lymphoma in, 57–58
 - vaccine therapy in, 63–64
- Dimerization, in PML-RAR α interactions, 86–88
- DNA
 - hypomethylation of, 343
 - in multiple myeloma, 158–160
- DNA binding
 - in PML-RAR α , 88–89
 - in RAR α (alpha receptor for retinoic acid), 79
- Donor leukocyte infusions, 280
- Dose intensity
 - in AIDS-associated lymphoma, 252–254
 - in diffuse aggressive lymphoma, 51–52
- E**
- Eastern Cooperative Oncology Group (ECOG)
 - on AML induction therapy, 209–210
 - on CHOP protocol, 51
 - on neutropenia, 202–204
 - on non-Hodgkin's lymphoma, 289–290, 290t
- EORTC
 - on ATRA, 133–134
 - on non-Hodgkin's lymphoma, 290t, 291
- Episomes, 31–32
 - in Burkitt's lymphoma, 36
- Epstein-Barr virus, 27–38
 - in Burkitt's lymphoma, 35–36
 - characterization of, 31–32
 - detection of, 32
 - gene expression in, 29
 - in HIV-associated lymphoma, 37–38, 245–246
 - in Hodgkin's disease, 36–37
 - immune response to, 31
 - latent infection of, 28–30
 - and lymphoma, 27–38
 - lytic infection of, 30–31
 - in nasal lymphoma, 38
 - neoplastic diseases and latency of, 29
 - in NK-cell lymphoma, 38
 - in posttransplantation lymphoproliferative disorders (PT-LPD), 18–19, 32–35
 - serologic studies of, 27–28
 - in T-cell lymphoma, 38
 - vs. human herpes virus, 27
- E-region, in RAR α , 81–83
- Erythropoietin
 - for B-cell malignancies, 288
 - for myelodysplasia, 285, 342, 352–353
- Etretinate, 227
- European APL 91 study, 130–132
- European Study Group, on erythropoietin, 288
- F**
- FAB classification, 336–337
- Fludarabine, 229

Fluorescent *in situ* hybridization (FISH), 159
Follicular center cells, 3
Follicular colonization, 12
Follicular lymphoma, 2–3
French Lymphoma Trials Group (GELA), 52–53
French Myeloma Intergroup trial, 177
French-American-British (FAB) group, 335–337
Fungal infection, 207–210
Fusion toxin therapy, for cutaneous T-cell lymphoma, 233–234
Fusion variants, in PML-RAR α , 86–88

G

Gallium-67 citrate imaging, 49–50
Gamma interferon, for chronic myeloid leukemia (CML), 279
GELA study
 on diffuse aggressive lymphoma, 52–53
 on non-Hodgkin's lymphoma, 290, 290t
Gene expression, in Epstein-Barr virus, 29
Gene structure, of acute promyelocytic leukemia, 76–78
Gene translocations. *See* Chromosome, translocation of
German CML Study Group, 277
German Myeloma Treatment Group, 288
Giant cells, in anaplastic large cell lymphoma (ALCL), 16
GIMEMA, 133–134
Graft-versus-host disease (GVHD)
 in acute myeloid leukemia, 283
 in bone-marrow transplant, 347
 in multiple myeloma transplantation, 184
Graft-versus-leukemic effect (GVL), 324–325
Granulocyte-macrophage colony stimulating factor (GM-CSF)
 antimicrobial function of, 207–210
 in autocrine/paracrine loops, 216–218
 for B-cell malignancies, 268–270
 for leukemia neutropenia, 201–202, 201t
 in leukemic cell proliferation, 196
 for myelodysplasia, 285, 336, 352
 in S phase cycle cell recruitment, 210–212

H

HAMA (human antimouse antibodies), 231–232
Helicobacter pylori, in mucosa-associated lymphoid tissue (MALT), 12–13

Hematologic malignancies, novel approaches to, 275–296
 acute myeloid leukemia (AML) in, 281–284 (*See also* Acute myeloid leukemia (AML))
 alpha interferon in, 275
 B-cell malignancies in, 286–289 (*See also* B-cell malignancies, novel approaches to)
 chronic myeloid leukemia (CML) in, 276–281 (*See also* Chronic myeloid leukemia (CML))
 future directions in, 294–295
 myelodysplasia in, 284–286 (*See also* Myelodysplasia)
 non-Hodgkin's lymphoma in, 289–294 (*See also* Non-Hodgkin's lymphoma, novel approaches to)
Hematopoietic growth factors, and leukemia, 195–219
 antimicrobial function enhancement in, 207–210 (*See also* Antimicrobial function enhancement, in leukemia)
 autocrine/paracrine loop interruption in, 216–218
 cell differentiation induction in, 214
 cytokines in, 214–216
 leukemic cell proliferation in, 196–199 (*See also* Leukemic cell proliferation, growth factors on)
 neutropenia reduction in, 199–207 (*See also* Neutropenia, in leukemia)
 S phase cell recruitment in, 210–214 (*See also* S phase cell recruitment)
 stem cell protection in, 218–219
Hematopoietic growth factors, in myelodysplasia, 352–353
Hematopoietic stem cells, in multiple myeloma, 180–181
The Hemophilia Malignancy Study Group, 241–242
Herpes virus, vs. Epstein-Barr virus, 27
Heterodimerization, in PML-RAR α interactions, 87–88
Hexamethylene bisacetamide, 342
High-dose sequential chemotherapy (HDSC), 54
Histiocytic lymphoma, 2
Histone acetylation, 81–83, 82f
HIV-associated lymphoma. *See also* AIDS-associated lymphoma
 Epstein-Barr virus in, 37–38, 245–246
HL-60 cells, in retinoic acid resistance, 99–100

Hodgkin's disease, Epstein-Barr virus in, 36–37
Human antimouse antibodies (HAMA), 231–232
Human response elements (HREs), in RAR α (alpha receptor for retinoic acid), 79–81
Hydroxyurea (HU), 276–277, 277t

I

Idarubicin, 133
Idiotype, 267
Id-KLH immunization, 268–270, 269t
Immortalization, of Epstein-Barr virus, 29
Immune response
 to Epstein-Barr virus, 31
 T-cells and, 267–272
Immunodeficiency disorders
 latency gene expression in, 29
 lymphoproliferative disorders as, 18
Immunofluorescence assays, 31
Immunoglobulin receptors, in B-cell malignancies, 267–272
Immunomodulation
 for acute myeloid leukemia (AML), 283–284
 posttransplant, in multiple myeloma, 186–187
Immunophenotype, in non-Hodgkin's lymphoma classification, 9
Immunotherapy, for diffuse aggressive lymphoma, 62–64
 adoptive immunotherapy in, 64
 immunotoxins in, 63
 monoclonal antibodies in, 62–63
 radioimmunotherapy in, 63
 vaccine therapy in, 63–64
Immunotoxins, for diffuse aggressive lymphoma, 63
Infection, non-clonal vs. clonal, 30f
Interferon
 for chronic myeloid leukemia (CML), 276–278, 277t
 for myelodysplasia, 342
Interleukin
 for acute myeloid leukemia (AML), 281–283, 282t
 in autocrine growth mechanism, 216–218
 for B-cell malignancies, 270, 288, 292
 for bone marrow transplants, 291–292
 for cutaneous T-cell lymphoma, 228
 for multiple myeloma, 162–163
 for myelodysplasia, 353

 for non-Hodgkin's lymphoma, 291–292
Intermediately differentiated lymphocytic lymphoma (IDLL), 10
International Lymphoma Study Group (ILSG), 7
International Non-Hodgkin's Lymphoma Risk Factor Project, 251
International Prognostic Index, 9
 in diffuse aggressive lymphomas, 49t
International Prognostic Scoring System (IPSS), 336–337
Iodine-labeled M195, 284
Isoform differentiation, in PML-RAR α , 85–86
Isotretinoin, for cutaneous T-cell lymphoma, 227
Italian Cooperative Study Group, 276–277

J

Japan Adult Leukemia Study Group (JALSG), 129–130

K

Kaposi's sarcoma herpes virus (KSHV), 246–247
Kiel classification
 in non-Hodgkin's lymphoma, 2–4
 updated, in non-Hodgkin's lymphoma, 6–7, 6t
Kouseisho Leukemia Study Group, 277–278

L

Lactate dehydrogenase, in acute lymphoblastic leukemia, 316
L-asparaginase, 319–320
Latent infection, of Epstein-Barr virus, 28–30
Leukemia
 acute lymphoblastic, 307–327 (*See also* Acute lymphoblastic leukemia)
 acute myelogenous, 195–219 (*See also* Hematopoietic growth factors, and leukemia)
 acute myeloid, 281–284 (*See also* Acute myeloid leukemia)
 acute promyelocytic (*See* Acute promyelocytic leukemia, current approaches to; Acute promyelocytic leukemia, molecular biology of; Acute promyelocytic leukemia, molecular diagnostics for)
 all-*trans* retinoic acid (ATRA) for, 129–130, 279
 alpha interferon for, 275

Leukemia (*Continued*)

- antimicrobial function enhancement in, 207–210
- arsenic compounds for, 141
- Australian Leukemia Study Group on, 138–139
- bone marrow transplantation for, 283
- Cancer and Leukemia Group B study on, 205, 276
- cellular expression of, 78–79
- chemotherapy for, 276–277, 277t
- chromosome translocation in, 76t, 313–314
- chronic lymphocytic, 11
- chronic myeloid, 276–281 (*See also* Chronic myeloid leukemia)
- cytarabine for, 278–279
- gamma interferon for, 279
- gene structure of, 76–78
- graft-*versus*-host disease (GVHD) in, 283
- granulocyte-macrophage colony stimulating factor (GM-CSF) for, 201–202, 201t
- hairy cell, 229, 289
- interferon for, 276–278, 277t
- interleukin for, 281–283, 282t
- Japan Adult Leukemia Study Group (JALSG) on, 129–130
- Kouseisho Leukemia Study Group on, 277–278
- lactate dehydrogenase in, 316
- magnetic field exposure on, 309
- M.D. Anderson Cancer Center on, 276
- monoclonal antibodies for, 284
- neutropenia in, 199–207 (*See also* Neutropenia, in leukemia)
- postremission therapy for, 135–136
- prognostic factors for, 136–137
- retinoic acid resistance in, 98–99
- retinoic acid syndrome (RAS) in, 138
- RT-PCR in, 108–110
- stem cell transplants for, 141–142
- thrombocytopenia in, 315–316
- Leukemic cell proliferation, growth factors on, 196–199
 - AML blast receptors in, 196–197, 197t
 - GM-CSF in, 196
 - multiple growth factors in, 198
 - thrombopoietin (TPO) in, 197
 - tumor necrosis factor (TNF) in, 197–198
- Ligand binding domain (LBD), in RAR α (alpha receptor for retinoic acid), 79
- Low dose m-BACOD regimen, 252, 252t

- Low-grade lymphoma of mucosa-associated lymphoid tissue (MALT), in non-Hodgkin's lymphoma classification, 12–13, 13f
- Lukes-Collins classification, in non-Hodgkin's lymphoma classification, 2–4, 3t
- Lymphoblastic lymphoma, therapy for, 58–60
 - cell structure in, 58
 - remission factors in, 59–60
 - survival rate in, 58–59
- Lymphocytes, in Epstein-Barr viral infection, 29
- Lymphoid cells, 3
 - Epstein-Barr lytic infection of, 30–31
- Lymphokine-activated killer (LAK) cells, 281
- Lymphoma. *See also* specific types
 - AIDS-associated, 241–260 (*See also* AIDS-associated lymphoma)
 - B-cell (*See* B-cell lymphoma)
 - cutaneous T-cell, 227–237 (*See also* Cutaneous T-cell lymphoma)
 - diffuse aggressive, 47–64 (*See also* Diffuse aggressive lymphoma)
 - histiocytic, 2
 - non-Hodgkin's, 1–20 (*See also* Non-Hodgkin's lymphoma, classification of)
 - Lytic infection, of Epstein-Barr virus, 30–31

M

- M195, 284
- Magnetic field exposure, and leukemia, 309
- Malignancies
 - B-cell, CD4 cells in, 270
 - B-cell, cytokines in, 268, 269t
 - hematologic, novel approaches to, 275–296 (*See also* Hematologic malignancies, novel approaches to)
 - The Hemophilia Malignancy Study Group on, 241–242
- Mantle cell lymphoma, in non-Hodgkin's lymphoma classification, 9–11, 10f
- Marginal zone lymphoma, in non-Hodgkin's lymphoma classification, 11–12
- Mayo Clinic, on erythropoietin, 288
- m-BACOD regimen, 252, 252t
- M.D. Anderson Cancer Center, 133
 - on chronic myeloid leukemia, 276
- Memorial Sloan Kettering Group, 284
- Methotrexate, 314
- Microspeckles, 86

- Mineral-oil-induced plasmacytomas (MOPCs), 267–268
 - Monoclonal antibodies
 - for acute myeloid leukemia, 284
 - for cutaneous T-cell lymphoma, 231–233
 - for diffuse aggressive lymphoma, 62–63
 - for non-Hodgkin's lymphoma, 293
 - Monocytoid B cells, 11
 - Monocytoid B-cell lymphoma, in non-Hodgkin's lymphoma classification, 14, 14f
 - Mononucleosis, in Hodgkin's disease, 36
 - MRD, detection of, 109
 - Mucosa-associated lymphoid tissue (MALT), in non-Hodgkin's lymphoma classification, 12–13, 13f
 - Multicenter AIDS Cohort Study (MACS), 242
 - Multiple myeloma, prognosis in, 155–166
 - β 2-microglobulin in [[comp-l.c. Greek beta]], 161
 - C-reactive protein in, 162–163
 - cytogenetic abnormalities in, 158–160
 - cytokine activity factors in, 161–164
 - DNA content in, 158–160
 - future directions for, 165–166
 - host factors in, 164–165
 - IL-6 in, 162
 - IL-6 receptor in, soluble, 163
 - immunohistochemistry in, 161
 - oncogenes in, 160
 - phenotyping in, 161
 - plasma cell labeling index (PCLI) in, 155–157, 157t
 - plasma cell morphology in, 160–161
 - plasma cells in, circulating, 164
 - proliferation assays in, other, 157–158
 - regulatory cells in, 164
 - serum markers in, 163–164
 - tumor burden indicators in, 161–164
 - tumor suppressor genes in, 160
 - Multiple myeloma, transplantation for, 171–186
 - allogeneic transplants in, 181–184 (*See also* Allogeneic transplants)
 - autologous transplants in, 172–180
 - clinical endpoints in, 173–175, 174f, 175t
 - French Myeloma Intergroup trial on, 177
 - future perspectives in, 187–188
 - hematopoietic stem cells in, 180–181
 - high risk patients in, 178–179
 - late myeloma in, 175, 176t
 - newly diagnosed patients in, 176–177
 - phase II studies of, 172t
 - posttransplant immunomodulation in, 186–187
 - posttransplant myelodysplasia risk in, 179–180
 - posttransplant relapse in, 179
 - standard dose resistance and, 171
 - stem cell selection in, 181
 - tandem autotransplants in, 172–173, 176
 - Total Therapy trial in, 177
 - transplantation timing in, 178
 - tumor purging in, 181
 - Mycosis fungoides (MF), 227
 - Myelodysplasia, 284–286
 - chemotherapy for, 286
 - differentiating agent evaluation in, 285–286
 - erythropoietin for, 285
 - hematopoiesis in, 284
 - neutropenia in, 285
 - Myelodysplasia, therapy advances in, 335–355
 - allogeneic bone marrow transplantation in, 346, 352
 - apoptosis in, 335–336
 - conceptual categorization in, 337–338, 338f
 - hematopoietic growth factors in, 352–353
 - intensive chemotherapy for, 346, 348t–351t
 - international scoring system for, 336–337
 - low-dose chemotherapy in, 343–346, 344t–345t
 - noncytotoxic/‘differentiation’ therapy in, 338–343, 339t–341t
 - summary approach algorithm in, 354, 355f
 - therapies for, miscellaneous, 353–354
 - Myeloid leukemia cell lines, in retinoic acid resistance, 98–99
 - Myeloma
 - agents for, 286–288
 - multiple (*See* Multiple myeloma)
 - Myelosuppression, in AIDS-associated lymphoma, 254–255
- N**
- Nasal lymphoma, Epstein-Barr virus in, 38
 - National Cancer Institute
 - on HIV-seropositive hemophiliacs, 241–242
 - on purine nucleoside therapies, 229–230, 230t
 - on thymopentin, 235
 - NB4 cells
 - in ATRA mechanism, 142

- NB4 cells (*Continued*)
 in retinoic acid resistance, 100–102
 in retinoid response, 93
- Neurotoxicity, of purine analogues, 230
- Neutropenia, in leukemia, 199–207
 Cancer and Leukemia Group B study in, 205
 cytokines for AML in, 199–200, 200t
 disease-free survival rates in, 204f
 Eastern Cooperative Oncology Group trial on, 202–204
 GM-CSF in, recombinant, 201–202, 201t
 in myelodysplasia, 285
 overall survival rates in, 203f
 study design endpoints in, 201
 trial data summary in, 205–207, 206t
- New York trial, for ATRA, 129
- NK-cell
 lymphoma, Epstein-Barr virus in, 38
 neoplasms of, 8t
- Node-based marginal zone lymphoma, in non-Hodgkin's lymphoma classification, 14, 14f
- Noncytotoxic/'differentiation' therapy, 338–343, 339t–341t
- Non-Hodgkin's lymphoma, classification of, 1–20
 anaplastic large cell lymphoma (ALCL) in, 16–18, 17f
 future classification in, 20
 Kiel classification in, 2–4
 Kiel classification in, updated, 6–7, 6t
 low-grade lymphoma of mucosa-associated lymphoid tissue (MALT) in, 12–13, 13f
 Lukes-Collins classification in, 2–4, 3t
 mantle cell lymphoma in, 9–11, 10f
 marginal zone lymphoma in, 11–12
 monocytoid B-cell lymphoma in, 14, 14f
 node-based marginal zone lymphoma in, 14, 14f
 posttransplantation lymphoproliferative disorders (PT-LPD) in, 18–20
 Rappaport classification in, 1–2, 2t
 Revised European-American Lymphoma (REAL) classification in, 7–9, 8t
 splenic marginal zone lymphoma in, 14–16, 15f
 WHO classification in, 9
 Working Formulation in, 4–5, 5t
- Non-Hodgkin's lymphoma, novel approaches to, 289–294
 alpha interferon for, 289–291
 COPA regimen for, 290–291
 interleukin-2 for, 291–292
 interleukin-4 for, 292
 monoclonal antibodies in, 293
 vaccines for, 293–294
- Nordic Cooperative Group, 287–288, 287t
- Nordic Myeloma Study Group, 286
- North American Intergroup 0129 study, 132
- NPM-RAR α , 107
- Nuclear bodies (NB), in PML cellular expression, 78–79
- Nucleophosmin (NPM), 17–18, 60
- NuMA-RAR α , 107–108
- O**
- Oncogenes, in multiple myeloma, 160
- Organ transplants, Epstein-Barr virus in, 32, 34
- P**
- Papilloma viruses, 31
- Paracrine loops, 216–218
- PARMA trial, 56
- PBSC, 53–54
- Peripheral T-cell lymphomas (PTCL), therapy for, 61–62
- P-glycoprotein
 in drug resistance, 314
 in retinoic acid resistance, 103–104
- Phenotyping, in multiple myeloma, 161
- Philadelphia chromosome, 313–314, 318
- Plasma cell labeling index (PCLI), for multiple myeloma, 155–157, 157t
- Plasma cells, in multiple myeloma
 circulating, 164
 morphology of, 160–161
- Plasmacytomas, mineral-oil-induced, 267–268
- PLZF, 105
- PLZF-RAR α /RAR α -PLZF
 function of, 106–107
 structure of, 105–106
- PML gene
 cellular expression in, 78–79
 functional activity in, 79
 gene structure in, 76–78
- PML-RAR α
 ATRA-regulated gene expression in, 94–95
 breakpoint regions in, 84–85
 DNA binding in, 88–89
 fusion variants in, 86–88
 isoform differentiation in, 85–86
 in leukemogenesis, 142
 overexpression of, 93–94

subcellular localization of, 86
transcriptional activity in, 88–89
in vitro functional studies for, 89
in vivo functional studies for, 89–91
Pneumocystis carinii, 229–230
prophylactic regimens for, 242
Polymerase chain reaction (PCR)
for Epstein-Barr virus detection, 32 (*See also* Reverse transcription-polymerase chain reaction (RT-PCR))
for immortalized B-cells, 29
Polymorphic B-cell hyperplasia, 18–19
Postremission therapy, for acute promyelocytic leukemia, 135–136
Posttransplant immunomodulation, in multiple myeloma, 186–187
Posttransplant lymphomas, *vs.* HIV-associated lymphomas, 244t
Posttransplant myelodysplasia risk, in multiple myeloma, 179–180
Posttransplant relapse, in multiple myeloma, 179
Posttransplantation lymphoproliferative disorders (PT-LPD)
Epstein-Barr virus in, 32–35
in non-Hodgkin's lymphoma classification, 18–20
Primary CNS lymphoma, 242
in AIDS-associated lymphoma, 257–259
Prognostic factors, for acute promyelocytic leukemia, 136–137
Proliferation assays, for multiple myeloma, 157–158
Proline, 77
ProMACE, 270
Promyelocytic leukemia. *See* Acute promyelocytic leukemia
Psoralen, 236
Purine analogue therapy, for cutaneous T-cell lymphoma, 229–231
Purine nucleotide phosphorylase, 231
PUVA, 228, 237

R

Radiation exposure, on leukemia, 308–309
Radioimmunotherapy, for diffuse aggressive lymphoma, 63
Radiotherapy
for initial treatment of diffuse aggressive lymphomas, 50–51
for relapsed diffuse aggressive lymphomas, 56
Rappaport classification, in non-Hodgkin's lymphoma classification, 1–2, 2t

RAR α (alpha receptor for retinoic acid), 75, 79–84
E-region/ligand binding domain (LBD) in, 81–83
expression heterogeneity in, 83–84
gene promoter model for, 82f
and nuclear receptor gene superfamily, 79–81
retinoid X receptors (RXRs) in, 80, 82f
structure of, 80f
RAR α fusion proteins, alternative, 104–108
NPM-RAR α in, 107
NuMA-RAR α in, 107–108
overview of, 104
PLZF as, 105
PLZF-RAR α /RAR α -PLZF function in, 106–107
PLZF-RAR α /RAR α -PLZF structure in, 105–106
RAR α -PML, detection of, 110–111
RARE (retinoic acid response elements) in heterogeneity of RAR expression, 84
in HRE specificity, 80
in PML-RAR α isoforms, 85–86
Reed-Sternberg cells, 245
Refractory Anemia with Excess Blasts (RAEB), 338, 352
Refractory conditions
in acute lymphoblastic leukemia, 323–324
in AIDS-associated lymphoma, 256
Resistance, to B-cell malignancies, 267–272.
See also B-cell malignancies, resistance to
Retinoblastoma, on AML blasts, 218
Retinoic acid
alpha receptor for, 75, 79–84 (*See also* RAR α)
for diffuse aggressive lymphoma, 62
response element for (*See* RARE (retinoic acid response elements))
Retinoic acid resistance, 97–104
bcl-2 gene in, 104
fresh APL cell studies in, 102–103
HL-60 cells in, 99–100
in myeloid leukemia cell lines, 98–99
NB4 cells in, 100–102
P-glycoprotein in, 103–104
pharmacologic *vs.* cellular basis of, 97–98
Retinoic acid syndrome (RAS)
in acute promyelocytic leukemia, 138
in myelodysplasia, 342
Retinoid response, 92–97
ATRA modulated genes in, 96

Retinoid response (*Continued*)
 ATRA-regulated PML-RAR α gene expression in, 94–95
 bcl-2 role in, 94
 nuclear reorganization in, 96–97
 PML-RAR α overexpression in, 93–94
 RXR-mediated gene expression in, 95–96
 success of ATRA treatment and, 92–93
 in vitro NB4 cell line studies in, 93
Retinoid X receptors (RXRs), 80, 82f
 on retinoid response gene expression, 95–96
Retinoids
 for cutaneous T-cell lymphoma, 227–228
 toxicity profile of, 228
Reverse transcription-polymerase chain reaction (RT-PCR), for acute promyelocytic leukemia, 108–110
Revised European-American Lymphoma (REAL) classification, in non-Hodgkin's lymphoma classification, 7–9, 8t
RING motif, 77
S
S phase cell recruitment, 210–214
 apoptosis in, 211–212
 cytokines as priming agents in, 212, 213t
 in vivo priming in, 210–211
Sanctuary sites, 321–322
Second-line therapy, for AIDS-associated lymphoma, 256
Serology, of Epstein-Barr virus, 27–28
Serum markers, for multiple myeloma, 163–164
Sezary syndrome, 227
Small noncleaved cell lymphoma (SNCL), therapy for, 57–58
Splenic marginal zone lymphoma, in non-Hodgkin's lymphoma classification, 14–16, 15f
Stem cell
 for diffuse aggressive lymphoma, 52–53, 53t
 protection of, 218–219
Stem cell transplants
 for acute promyelocytic leukemia, 141–142
 for multiple myeloma (*See* Multiple myeloma, transplantation for)
Subcellular localization, of PML-RAR α , 86
Survival rates

 for diffuse aggressive lymphomas, 49t
 for diffuse aggressive lymphomas, bone marrow transplantation in, 56
 in lymphoblastic lymphoma, 58–59

T

T-101, 231–232
Tandem autotransplants, for multiple myeloma, 172–173, 176
T-cell
 in AIDS-associated lymphoma, 247–248
 in bone-marrow transplant, 347
 in Epstein-Barr viral infection, 29, 31
 and immunity, 267–272
T-cell lymphoma, 4, 6–7, 8t
 as anaplastic large cell lymphoma, 17
 Epstein-Barr virus in, 38
 ontogeny schematic of, 311f
Thrombocytopenia
 in acute lymphoblastic leukemia, 315–316
 in myelodysplasia, 285
Thrombopoietin
 in leukemic cell proliferation, 197
 in myelodysplasia, 285
Thymopentin, for cutaneous T-cell lymphoma, 234–235
Topotecan, 346
Total Therapy trial, 177
Toxin modalities, for MF/SS, 232, 232t
Toxoplasmosis, 258
Translocation. *See* Chromosome, translocation of
Transplantation therapy, for diffuse aggressive lymphoma, 52–53, 53t
Tretinoin, 140–141
Trilineage response, 342
Tumor burden indicators, in multiple myeloma, 161–164
Tumor necrosis factor (TNF)
 in autocrine/paracrine loop, 218
 in leukemic cell proliferation, 197–198
Tumor resistance, cellular mechanisms of, 267–268
Tumor suppressor genes, in multiple myeloma, 160
U
University of Arkansas
 on multiple myeloma, newly diagnosed patients in, 177
 on tandem autotransplants, 172–175

V

- Vaccination, against immunoglobulin receptor, 267–272
- Vaccines
 - for diffuse aggressive lymphoma, 63–64
 - for non-Hodgkin's lymphoma, 293–294
- Vidarabine, 229
- Virions, 27, 28f
- Virus capsid antigen (VCA), 31
- Vitamin D₃, 342–343

W

- Whole-brain radiation therapy, 322
- Working Formulation, in non-Hodgkin's lymphoma classification, 4–5, 5t
- World Health Organization (WHO)
 - on lymphoproliferative disorders, 18
 - on non-Hodgkin's lymphoma classification, 9

Z

- Zidovudine (AZT), on NHL, 242